1. Home
  2. SNGX vs ULY Comparison

SNGX vs ULY Comparison

Compare SNGX & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • ULY
  • Stock Information
  • Founded
  • SNGX 1987
  • ULY 2013
  • Country
  • SNGX United States
  • ULY United States
  • Employees
  • SNGX N/A
  • ULY N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • ULY
  • Sector
  • SNGX Health Care
  • ULY
  • Exchange
  • SNGX Nasdaq
  • ULY Nasdaq
  • Market Cap
  • SNGX 7.4M
  • ULY 6.7M
  • IPO Year
  • SNGX 1987
  • ULY N/A
  • Fundamental
  • Price
  • SNGX $2.39
  • ULY $0.53
  • Analyst Decision
  • SNGX
  • ULY Strong Buy
  • Analyst Count
  • SNGX 0
  • ULY 1
  • Target Price
  • SNGX N/A
  • ULY $1.50
  • AVG Volume (30 Days)
  • SNGX 44.9K
  • ULY 58.2K
  • Earning Date
  • SNGX 03-14-2025
  • ULY 03-13-2025
  • Dividend Yield
  • SNGX N/A
  • ULY N/A
  • EPS Growth
  • SNGX N/A
  • ULY N/A
  • EPS
  • SNGX N/A
  • ULY 7.18
  • Revenue
  • SNGX $364,183.00
  • ULY $155,926,000.00
  • Revenue This Year
  • SNGX N/A
  • ULY N/A
  • Revenue Next Year
  • SNGX $76.64
  • ULY $4.29
  • P/E Ratio
  • SNGX N/A
  • ULY $0.07
  • Revenue Growth
  • SNGX N/A
  • ULY N/A
  • 52 Week Low
  • SNGX $1.83
  • ULY $0.41
  • 52 Week High
  • SNGX $14.88
  • ULY $3.45
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 43.83
  • ULY 53.89
  • Support Level
  • SNGX $2.25
  • ULY $0.48
  • Resistance Level
  • SNGX $2.60
  • ULY $0.54
  • Average True Range (ATR)
  • SNGX 0.15
  • ULY 0.04
  • MACD
  • SNGX 0.03
  • ULY 0.00
  • Stochastic Oscillator
  • SNGX 52.27
  • ULY 74.95

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and lead to long wait times. Urgently offers an innovative alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

Share on Social Networks: